Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Oertel, Susanne ^a   Thiemann, Markus ^a   Richter, Karsten ^b   Weber, Klaus J ^a   Huber, Peter E ^b   Perez, Ramon L ^b   Brons, Stephan ^c   Bischof, Marc ^a   Kulozik, Andreas E ^c   Ehemann, Volker ^a   Debus, Jürgen ^a   Blattmann, Claudia ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Heavy ion radiotherapy; Histone deacetylase inhibition; Infantile sarcoma; Saha; Suberoylanilide hydroxamic acid

Indexed keywords

HISTONE H2AX; PROTEIN P21; PROTEIN P53; VORINOSTAT; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; H2AFX PROTEIN, HUMAN; HEAVY ION; HISTONE; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CHILDHOOD CANCER; DOWN REGULATION; HEAVY ION RADIATION; HUMAN; HUMAN CELL; OSTEOBLAST; PROTEIN EXPRESSION; RADIOSENSITIVITY; RHABDOMYOSARCOMA; SARCOMA; CELL SEPARATION; CHEMISTRY; CHROMATIN; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEWBORN; RADIOTHERAPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SEPARATION; CHROMATIN; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLOW CYTOMETRY; HEAVY IONS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INFANT, NEWBORN; MICROSCOPY, CONFOCAL; OSTEOBLASTS; RADIOTHERAPY; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053173679     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-119     Document Type: Article

References (34)

1. Minucci S, Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51. 10.1038/nrc1779, 16397526.
2. Wilson AJ, Chueh AC, Tögel L, et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010, 70(2):609-620. 10.1158/0008-5472.CAN-09-2327, 2939837, 20068171.
3. Furchert SE, Lanvers-Kaminsky C, Jürgens H, et al. Inhibitor of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007, 120:1787-1794. 10.1002/ijc.22401, 17230517.
4. Lee M-J, Kim YS, Kummar S, et al. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008, 20:639-649. 10.1097/CCO.0b013e3283127095, 18841045.
5. Dalgard CL, Van Quil KR, O'Brien JM, et al. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008, 14(10):3113-3123. 10.1158/1078-0432.CCR-07-4836, 18483379.
6. Yang C, Choy E, Hornicek FJ, et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 2011, 67(2):439-46. 10.1007/s00280-010-1344-7, 20461381.
7. Blattmann C, Oertel S, Ehemann V, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010, 78(1):237-245. 10.1016/j.ijrobp.2010.03.010, 20646843.
8. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007, 25:4051-4056. 10.1200/JCO.2007.11.6202, 17827453.
9. Karagiannis TC, El Osta A. Modulation of cellular radiation response by histone deacetylase inhibitors. Oncogene 2006, 25:3885-3893. 10.1038/sj.onc.1209417, 16462761.
10. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5:1967-74. 10.1158/1535-7163.MCT-06-0022, 16928817.
11. Xu Y, Price BD. Chromatin dynamics and the repair of DANN double strand breaks. Cell Cycle 2011, 10(2):261-267. 10.4161/cc.10.2.14543, 21212734.
12. Hada M, Sutherland BM. Spectrum of complex DNA damages depends on the incident radiation. Radiat Res 2006, 165(2):223-30. 10.1667/RR3498.1, 16435920.
13. Blattmann C, Oertel S, Schulz-Ertner D, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 2010, 10:96. 10.1186/1471-2407-10-96, 2846886, 20226028.
14. Kano M, Yamada S, Hoshino I, et al. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29(11):4433-8.
15. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5:85-91.
16. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-73. 10.1200/JCO.2005.01.9679, 16330674.
17. Baschnagel A, Russo A, Burgan WE, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8(6):1589-95. 10.1158/1535-7163.MCT-09-0038, 19509253.
18. Vasirredy RS, Shung CN, Cempaka NL, et al. H2AX phosphorylation screens from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype. Br J Cancer 2010, 102(10):1511-1518. 10.1038/sj.bjc.6605666, 2869166, 20461094.
19. Chung YL, Lee MY, Pui NN. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009, 30(8):1387-1397. 10.1093/carcin/bgp079, 19351790.
20. Chinnaiyan P, Vallabhaneni G, Armstrong E, et al. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62:223-9. 10.1016/j.ijrobp.2004.12.088, 15850925.
21. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of χH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64:316-21. 10.1158/0008-5472.CAN-03-2630, 14729640.
22. Storch K, Eke I, Borgmann K, et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010, 70:3925-34. 10.1158/0008-5472.CAN-09-3848, 20442295.
23. Oishi T, et al. Proliferation and cell death of human glioblastoma cells after carbon-ion beam exposure: morphologic and morphometric analyses. Neuropathology 2008, 28:408-416. 10.1111/j.1440-1789.2008.00899.x, 18282165.
24. Hamada N, Tatsuhiko I, Masunaga S, et al. Recent advances in the Biology of heavy-ion cancer therapy. J Radiat Res 2010, 51:365-83. 10.1269/jrr.09137, 20679739.
25. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59(4):928-42. 10.1016/j.ijrobp.2004.03.005, 15234026.
26. Hollstein M, et al. p53 mutations in human cancers. Science 2001, 253:49-53.
27. Diller, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990, 10(11):5772-5781. 361354, 2233717.
28. Takahashi T, Fukawa T, Hirayama R, et al. In vitro interaction of high-LET heavy-ion irradiation and chemotherapeutic agents in two cell lines with different radiosensitivities and different p53 status. Anticancer Res 2010, 30(6):1961-7.
29. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24:4609-23. 10.1038/sj.onc.1208585, 15897906.
30. Takahashi A, Matsumoto H, Furusawa Y, et al. Apoptosis induced by high-LET radiations is not affected by cellular p53 gene status. Int J Radiat Biol 2005, 81:581-6. 10.1080/09553000500280484, 16298939.
31. Blakely EA, Chang PY. Biology of charged particles. Cancer J 2009, 15:271-84. 10.1097/PPO.0b013e3181b666c5, 19672143.
32. Huo JX, Metz SA, Li GD. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ 2004, 11(1):99-109. 10.1038/sj.cdd.4401322, 12970678.
33. Banath J, MacPhail S, Olive P. Radiation Sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell cines. Cancer Res 2004, 64:7144-9. 10.1158/0008-5472.CAN-04-1433, 15466212.
34. Mills J, Hricik T, Siddiqi S, et al. Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther 2011, (10):313-323.